• Zhaoke Ophthalmology entered a five-year exclusive distribution and promotion deal with Pharmentum Biopharma for epinastine hydrochloride eye drops in China.
• Agreement covers all sales channels in mainland China, excluding Hong Kong, Macau, Taiwan.
• Contract renews once to 10 years if Pharmentum meets at least 80% of a cumulative procurement target, absent material breach.
• Epinastine hydrochloride eye drops received China marketing clearance on Nov. 19, 2025 for seasonal allergic conjunctivitis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhaoke Ophthalmology Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260812-12281226), on August 12, 2026, and is solely responsible for the information contained therein.